These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 3111692)

  • 1. Pharmacology of platelet-inhibitory drugs, anticoagulants, and thrombolytic agents.
    Mehta JL; Kitchens CS
    Cardiovasc Clin; 1987; 18(1):163-79. PubMed ID: 3111692
    [No Abstract]   [Full Text] [Related]  

  • 2. A monoclonal antibody reacting with platelets for monitoring thrombolysis.
    Wang GJ; Oster ZH; Som P; Zamora PO
    Int J Rad Appl Instrum B; 1991; 18(3):275-80. PubMed ID: 1906449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drugs that alter the hemostatic mechanism.
    Rackear DG
    Vet Clin North Am Small Anim Pract; 1988 Jan; 18(1):67-77. PubMed ID: 3282386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Thrombolytics and their use].
    Alessi MC; Juhan-Vague I
    Rev Prat; 1999 Oct; 49(15):1654-8. PubMed ID: 10581996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Behavior of postoperative adhesions after intraperitoneal administration of fibrinolytic drugs in a rat model].
    Stapel A; Geissler N; Mlasowsky B; Jung D
    Langenbecks Arch Chir; 1997; 382(1):33-6. PubMed ID: 9157230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Registry of prospective clinical trials second report.
    Verstraete M
    Thromb Haemost; 1976 Aug; 36(1):239-50. PubMed ID: 1036815
    [No Abstract]   [Full Text] [Related]  

  • 7. [Platelet activation in the early phases of acute myocardial infarction].
    Salvioni A; Giraldi F; Assanelli E; Lauri G; Grazi M; Pardea S; Marenzi G
    Cardiologia; 1998 Aug; 43(8):825-32. PubMed ID: 9808873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Studies on fibrinolytic agent-platelet interaction (author's transl)].
    Mishina Y; Watada M
    Nihon Ketsueki Gakkai Zasshi; 1974 Apr; 37(2):154-60. PubMed ID: 4277931
    [No Abstract]   [Full Text] [Related]  

  • 9. In vitro analysis of synergistic effects of fibrinolytic agents and prostacyclin analogues.
    Spiecker M; Heinke B; Meyer J; Darius H
    Haemostasis; 1997; 27(4):184-92. PubMed ID: 9483173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effects of basic therapy of ischemic heart disease on vascular-platelet hemostasis during myocardial revascularization].
    Vorob'eva NA; Nedashkovskiĭ EV
    Anesteziol Reanimatol; 2001; (3):47-50. PubMed ID: 11510359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of recombinant-tissue plasminogen activator, low molecular weight urokinase and unfractionated heparin on platelet aggregation.
    Paolini R; Casonato A; Boeri G; Luzzatto G; Girolami A; Sasahara AA; Cella G
    J Med; 1993; 24(2-3):113-30. PubMed ID: 8409776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological interactions between ditazole and anticoagulant drugs.
    Caprino L; Falchetti R; Borrelli F
    Arzneimittelforschung; 1975; 25(12):1920-3. PubMed ID: 56180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Platelet activation by fibrinolytic agents: a potential mechanism for resistance to thrombolysis and reocclusion after successful thrombolysis.
    Leopold JA; Loscalzo J
    Coron Artery Dis; 1995 Dec; 6(12):923-9. PubMed ID: 8723013
    [No Abstract]   [Full Text] [Related]  

  • 14. Effect of thrombolytic therapy on pulmonary-capillary blood volume in patients with pulmonary embolism.
    Sharma GV; Burleson VA; Sasahara AA
    N Engl J Med; 1980 Oct; 303(15):842-5. PubMed ID: 7412801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pharmacology of fibrinolytics].
    Klöcking HP
    Z Gesamte Inn Med; 1979 Jan; 34(1):22-8. PubMed ID: 373275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Structure, function and use of fibrinolysis-promoting and inhibiting factors].
    Bachmann F
    Arzneimittelforschung; 1988 Mar; 38(3A):474-8. PubMed ID: 3134901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Combined effects of PGI2 and thrombin inhibitors or fibrinolytic agent on platelet aggregation and disaggregation].
    Takahashi H; Nagayama R; Fuse I; Hattori A; Shibata A
    Rinsho Ketsueki; 1984 Jul; 25(7):998-1003. PubMed ID: 6389931
    [No Abstract]   [Full Text] [Related]  

  • 18. Synergism of tissue-type plasminogen activator (t-PA) and single-chain urokinase-type plasminogen activator (scu-PA) on clot lysis in vitro and a mechanism for this effect.
    Gurewich V; Pannell R
    Thromb Haemost; 1987 Jun; 57(3):372-3. PubMed ID: 3116707
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of epsilon-aminocaproyl-S-benzyl-L-cysteine on the activity of plasminogen activators.
    Bruzgo I; Midura-Nowaczek K; Kaczyńska J; Krajewska D
    Acta Pol Pharm; 2009; 66(1):37-40. PubMed ID: 19226966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of superoxide production in human neutrophils by combinations of heparin and thrombolytic agents.
    Riesenberg K; Schlaeffer F; Katz A; Levy R
    Br Heart J; 1995 Jan; 73(1):14-9. PubMed ID: 7888254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.